Stem Cells: Put to the test
Checking that a new drug candidate does not trigger a potentially lethal heart arrhythmia called torsades de pointes has become an essential and costly part of the drug development process over the past two decades. A drug-induced increase in the length of time it takes for heart muscle cells to reset so that they are ready for the next heartbeat, which is reflected by an increase in the QT interval on the surface electrocardiogram (ECG), is associated with an increased risk of torsades de pointes.
Extensive research has revealed that the most common cause for drug-induced increases in the QT interval is the blocking of a potassium ion channel called hERG (Roden, 2016). As a result, early in the drug development process, candidate small molecules are routinely screened for their ability to block hERG channels expressed in stable cell lines. Although this strategy has dramatically reduced the number of potentially harmful compounds that make it to clinical trials, it is costly in terms of time and resources. Furthermore, it eliminates many promising therapeutic compounds that may not actually cause torsades de pointes (Gintant et al., 2016). Indeed, some hERG blocking drugs, such as verapamil, do not increase the QT interval (Zhang et al., 1999), and there are various drugs that can increase the QT interval without causing torsades de pointes (such as ranolazine; Tzeis and Andrikopoulos, 2012). There is, therefore, a need for more cost effective and predictive models to address this safety issue.
Now, in eLife, Jean-Sebastien Hulot at the Icahn School of Medicine at Mount Sinai and colleagues – including Francesca Stillitano and Jens Hansen as joint first authors – report that heart muscle cells made from induced pluripotent stem cells might offer an answer to this problem (Stillitano et al., 2017).
Reprogramming somatic cells to become master stem cells called induced pluripotent stem cells (iPSCs for short) now provides the opportunity to generate any specific cell type present in the body that is genetically matched to the starting somatic cell (Takahashi et al., 2007; Yu et al., 2007). Previous studies have shown that heart muscle cells made from iPSCs from patients with inherited forms of long QT syndrome behave similarly to their own heart muscle cells (Moretti et al., 2010; Itzhaki et al., 2011). This suggests that iPSC-derived cells could be used as a model for evaluating whether potential new drugs might alter the QT interval in humans (Anson et al., 2011).
However, like all model systems, there are limitations. Most importantly, the heart muscle cells made by iPSCs are more similar to the heart muscle cells found in embryos than those found in adults (Yang et al., 2014), which may mean that they respond differently to drugs. A growing number of studies suggest that heart muscle cells produced by iPSCs do respond appropriately to drugs that are known to increase the QT interval in humans (Kitaguchi et al., 2016): however, we do not know whether these cells will faithfully reflect the responses of individual patients.
Stillitano et al. – who are based at Icahn, Sorbonne Universités and Cellectis Stem Cells – compare the responses of individual volunteers to a hERG blocking drug with the responses of iPSC-derived heart muscle cells generated from the same individuals (Figure 1). To do this, the team recruited 92 healthy and genetically diverse volunteers with normal baseline QT intervals and gave them a single dose of a drug called sotalol.

Reprogrammed skin cells can be used as models to test the cardiac safety of drug compounds.
Stillitano et al. gave healthy volunteers (top left) a single dose of the drug sotalol, and then used an electrocardiogram (ECG) to measure how the drug affected their QT interval, which represents the length of time it takes for their heart muscle cells to reset after they contract for a heartbeat. Skin samples were collected from the 10 volunteers with the highest sensitivity to sotalol and the 10 volunteers with the lowest sensitivity, and skin cells from each of the volunteers in these two groups were reprogrammed to make induced pluripotent stem cells (iPSCs; bottom left). These iPSCs were then exposed to conditions that caused them to differentiate and become heart muscle cells. Finally, multielectrode arrays (MEA; bottom right) were used to measure changes in field potential duration (which is a surrogate for the QT interval) in the cells.
As anticipated, some individuals were more sensitive to sotalol than others. Stillitano et al. then focused on the 10 volunteers with the lowest sensitivity to the drug (that is, those with the smallest increases in QT intervals) and the 10 volunteers with the highest sensitivity. Skin cells from both groups were reprogrammed to make iPSCs, and these were then used to make heart muscle cells. The cells from the high sensitivity group had larger increases in a quantity called the field potential duration (which is a surrogate for the QT interval in cell studies) in response to sotalol than those from the low sensitivity group.
One might predict that the cells in the high sensitivity group would also be more sensitive to other hERG blocking drugs, but there does not appear to be any difference in the responses of the two groups to a hERG blocker called E4031. Is this apparent difference in the way that cells respond to sotalol and E4031 caused by noise in the model system? Or is it the result of these drugs having distinct effects on the other ion channels and regulatory proteins that regulate the QT interval? For example, Stillitano et al. show that there are differences in the expression of several genes that regulate ion channels between the high and low sensitivity groups.
Although this work suggests that heart muscle cells produced by iPSCs may be useful models for testing the ability of potential new drugs to alter the QT interval in humans, important questions remain. Stillitano et al. removed cell lines from two of the volunteers that did not respond to E4031 from the study, and it is not clear whether these lines would confound the results. Furthermore, the responses of the iPSC-derived cells from the two groups of volunteers did not segregate perfectly. Was this due to imperfect reprogramming among the samples from different individuals and could characterizing more than one clone per subject overcome this limitation? Could better preparations of heart muscle cells improve the results? Would three dimensional heart tissue constructs composed of the multiple cell lineages present in the heart be better predictors of the volunteers’ responses to sotalol and other drugs?
Further analysis would ideally compare responses across all 92 volunteers involved in the study rather than just the most and least sensitive groups, but the realities of time and cost make such a study even more difficult. Nevertheless, this is the first clinical study to test the usefulness of iPSC-derived heart muscle cells as models of the response of specific individuals to drugs. In the case of drug-induced changes in QT intervals, these reprogrammed cells are found to be promisingly predictive. Future studies will undoubtedly improve the methodologies, and this model system will likely also prove valuable in testing other forms of drug-induced cardiotoxicity. This study begins to validate the concept that it may actually be possible to test how individuals would respond to drugs in clinical trials without putting them at risk.
References
-
Opportunities for use of human iPS cells in predictive toxicologyClinical Pharmacology & Therapeutics 89:754–758.https://doi.org/10.1038/clpt.2011.9
-
Evolution of strategies to improve preclinical cardiac safety testingNature Reviews Drug Discovery 15:457–471.https://doi.org/10.1038/nrd.2015.34
-
CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilitiesJournal of Pharmacological and Toxicological Methods 78:93–102.https://doi.org/10.1016/j.vascn.2015.12.002
-
Patient-specific induced pluripotent stem-cell models for long-QT syndromeNew England Journal of Medicine 363:1397–1409.https://doi.org/10.1056/NEJMoa0908679
-
Predicting drug-induced QT prolongation and torsades de pointesThe Journal of Physiology 594:2459–2468.https://doi.org/10.1113/JP270526
-
Antiarrhythmic properties of Ranolazine--from bench to bedsideExpert Opinion on Investigational Drugs 21:1733–1741.https://doi.org/10.1517/13543784.2012.716826
Article and author information
Author details
Publication history
Copyright
© 2017, Woon et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 712
- views
-
- 83
- downloads
-
- 1
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Developmental Biology
- Stem Cells and Regenerative Medicine
In holothurians, the regenerative process following evisceration involves the development of a ‘rudiment’ or ‘anlage’ at the injured end of the mesentery. This regenerating anlage plays a pivotal role in the formation of a new intestine. Despite its significance, our understanding of the molecular characteristics inherent to the constituent cells of this structure has remained limited. To address this gap, we employed state-of-the-art scRNA-seq and hybridization chain reaction fluorescent in situ hybridization analyses to discern the distinct cellular populations associated with the regeneration anlage. Through this approach, we successfully identified 13 distinct cell clusters. Among these, two clusters exhibit characteristics consistent with putative mesenchymal cells, while another four show features akin to coelomocyte cell populations. The remaining seven cell clusters collectively form a large group encompassing the coelomic epithelium of the regenerating anlage and mesentery. Within this large group of clusters, we recognized previously documented cell populations such as muscle precursors, neuroepithelial cells, and actively proliferating cells. Strikingly, our analysis provides data for identifying at least four other cellular populations that we define as the precursor cells of the growing anlage. Consequently, our findings strengthen the hypothesis that the coelomic epithelium of the anlage is a pluripotent tissue that gives rise to diverse cell types of the regenerating intestinal organ. Moreover, our results provide the initial view into the transcriptomic analysis of cell populations responsible for the amazing regenerative capabilities of echinoderms.
-
- Developmental Biology
- Stem Cells and Regenerative Medicine
Haploinsufficiency for GATA6 is associated with congenital heart disease (CHD) with variable comorbidity of pancreatic or diaphragm defects, although the etiology of disease is not well understood. Here, we used cardiac directed differentiation from human embryonic stem cells (hESCs) as a platform to study GATA6 function during early cardiogenesis. GATA6 loss-of-function hESCs had a profound impairment in cardiac progenitor cell (CPC) specification and cardiomyocyte (CM) generation due to early defects during the mesendoderm and lateral mesoderm patterning stages. Profiling by RNA-seq and CUT&RUN identified genes of the WNT and BMP programs regulated by GATA6 during early mesoderm patterning. Furthermore, interactome analysis detected GATA6 binding with developmental transcription factors and chromatin remodelers, suggesting cooperative regulation of cardiac lineage gene accessibility. We show that modulating WNT and BMP inputs during the first 48 hr of cardiac differentiation is sufficient to partially rescue CPC and CM defects in GATA6 heterozygous and homozygous mutant hESCs. This study provides evidence of the regulatory functions for GATA6 directing human precardiac mesoderm patterning during the earliest stages of cardiogenesis to further our understanding of haploinsufficiency causing CHD and the co-occurrence of cardiac and other organ defects caused by human GATA6 mutations.